Biocon in pact with Bristol-Myers for 'blockbuster' drug

Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb Company for Biocon's IN-105, a prandial
oral insulin product candidate. Under the terms of the agreement, Bristol-Myers Squibb will have the right to exercise an option to obtain an exclusive worldwide license to the program. Biocon will conduct clinical studies to further characterise

IN-105's clinical profile according to a pre-agreed development program up to the completion of Phase II.